Study of ED risk loses the signal by including past users of finasteride

There is a major limitation: the analysis included past and recent users of 5ARIs, as well as current users. Past users are defined as those who stopped taking a 5ARI at least 91 days before getting diagnosed or treated for ED. Recent users are those who last took the drug 31-90 days before diagnosis or treatment for ED.

Finasteride appears on Prescrire’s latest ‘Drugs to Avoid’ list

Prescrire, an independent patient safety organization based in France, has updated its Drugs to Avoid guide. Finasteride appears in the 2024 edition, and has also been included in past editions. The guide notes: Finasteride 1 mg, a 5-alpha reductase inhibitor, has very modest efficacy in androgenic alopecia in men: it increases hair density on the … Read more

Seeking a medical sign of genital numbness

Some post-5ARI patients experience genital numbness. This symptom can be assessed, but the tests are not easily accessible. This post gives an overview of medical tests which could yield signs of genital numbness and other abnormalities.

From LSD to Zoloft, drugs can leave lasting damage

SUMMARY: Post-drug disorders are not side effects that linger, but lasting changes that may be severe and irreversible. These disorders are linked to prescribed drugs as well as recreational drugs, and can arise after one dose, long-term use, or abuse. This post covers post-drug disorders linked to use of alcohol, hallucinogens, antidepressants, benzodiazepenes, isotretinoin (also … Read more

Firsthand experiences – Volume X: Saw palmetto & nettle

Men turn to saw palmetto, a plant-based supplement, because prescription drugs may be unavailable or too costly. Some see the palm supplement as having a lower risk of side effects. Regulators say it is safe, but online, it is not difficult to find reports of men with adverse experiences after using saw palmetto which resemble the post-finasteride disorder.

Since 1994, Merck has been aware of unresolved sexual dysfunction in men who stopped taking finasteride

Six months after discontinuing a Phase 3 finasteride trial, a man’s sexual adverse experience was unresolved. There were also 16 men whose drug-related sexual adverse experiences were unresolved at the conclusion of the trial.

The Merck files, part 2: Merck responds to regulatory concerns about persistent adverse effects of Propecia

In 2006, the Swedish Medical Products Agency asked Merck for an analysis of all adverse events affecting the male reproductive system which persisted after stopping Propecia. In subsequent documents, there is a back-and-forth between Merck and the Agency as to the validity of these reports and the overall safety concern. Merck used an arsenal of arguments to discount these reports and claim its own data is superior to postmarketing data.